CIDLID

Improving the quality of FMD vaccines by understanding the correlation of vaccine-induced protection with humoral and cellular immune responses (A643)

 
The scientific hypotheses underlying our research are, firstly, that viral antigenic phenotype can be predicted from capsid gene sequences; and secondly that there is a measurable T cell component to vaccine-induced protection and that strengthening this would improve efficacy and duration of immunity. Our specific objectives are:

(1) To define viral determinants of antigenicity and improve the selection of vaccine strains, particularly in Africa, where there is the widest diversity of circulating viruses and few tailor-made vaccine strains.
(2) To evaluate novel adjuvants that may enhance the potency and durability of vaccine-induced immunity.
(3) To define correlates of vaccine-mediated protection and to transfer technology to establish in vitro alternatives to live challenge as a means of assuring vaccine strain potency to laboratories in developing countries.

IAH Principal Investigator: Professor Satya Parida

IAH Co-investigators: Dr David Paton, Dr Madhuchhanda Mahapatra, Dr Jayne Hope, Dr Geraldine Taylor

UK Co-Investigators:
Professor Daniel Haydon, Faculty of Biomedical and Life Sciences, University of Glasgow
Dr Richard Reeve, Faculty of Biomedical and Life Sciences, University of Glasgow

Overseas Co-Investigators:
Dr Francois Maree, Onderstepoort Veterinary Institute, Agricultural Research Council
Dr Srinivasan Villuppanoor, Indian Immunologicals Ltd
Dr Nagendrakumar Singanallur, Indian Immunologicals Ltd
Dr Madhanmohan Muthukrishnan, Indian Immunologicals Ltd

Country involved: Eastern Africa (Eritrea, Ethiopia, Somalia, Uganda, Sudan, Kenya, Tanzania and Democratic Republic of Congo)
Duration: 36 months
     

 
CIDLID Home